Asset
EMVODODSTAT
PTC Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04439071 | phase2_3 | terminated | 2020-07-09 | 2022-07-20 | PTC Therapeutics | A Study to Evaluate Efficacy and Safety of PTC299 (Emvododstat) in Hospitalized Participants With Coronavirus (COVID-19) |
| NCT00508586 | phase1 | completed | 2007-11-01 | 2012-03-01 | PTC Therapeutics | PTC299 and Hormonal Agent for Treatment of Metastatic Breast Cancer |
| NCT00704821 | phase1 | terminated | 2008-07-03 | 2012-02-24 | PTC Therapeutics | PTC299 for Treatment of Advanced Cancer |
| NCT00911248 | phase2 | terminated | 2009-07-31 | 2012-03-31 | PTC Therapeutics | PTC299 for Treatment of Neurofibromatosis Type 2 |
| NCT03761069 | phase1 | terminated | 2018-10-29 | 2021-12-28 | PTC Therapeutics | Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias |
FDA applications (0)
This company has no applications containing this asset.